Moderna Reports Positive Results for Coronavirus Vaccine Candidate in Elderly Patients
Moderna (NASDAQ: MRNA) was again in the headlines on Wednesday, following hopeful news about its mRNA-1273 coronavirus vaccine candidate.
The company revealed that in a small, early-stage clinical trial, mRNA-1273 produced what Moderna described as "consistently high levels" of neutralizing antibodies that could provide immunity to the coronavirus. These levels are comparable to those produced by younger adults, according to the company, which made the claims in a presentation to the government's Centers for Disease Control and Prevention.
Image source: Getty Images.
Source Fool.com
